Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, shared on X:
“So great to see that Novartis drug with Lu177 received expanded approval for prostate cancer last week.
But these targeted radioligands (like radiation therapy) result in loss of NK and T cells. Low ALC. So imagine if there was a cytokine around to rescue these NK and T cells and protect the ALC? Just imagine. Go Lu177!”
You can also read:
Adaptive MR-Guided SBRT Shows Low Toxicity in Prostate Cancer
